



Accessory Spleen Only Detected Following Repeat Ultrasonographic Examinations: A Case Report

Sarici A^{1*}, Erkuş MA¹, Kaya E¹, Kuku I¹, Slocum A² and Kandemir MH³

¹Department of Hematology, Turgut Ozal Medical Center, Inonu University, Turkey

²Department of Internal Disease, Turgut Ozal Medical Center, Inonu University, Turkey

³Department of Internal Medicine, Turgut Ozal Medical Center, Inonu University, Turkey

*Corresponding author: Sarici A, Department of Hematology, Turgut Ozal Medical Center, Inonu University, Turkey, Tel: +5323862126; E-mail: ahmetsarici44@gmail.com

Received Date: 30 April 2019; Accepted Date: 28 May 2019; Published Date: 10 June 2019

Abstract

Primary immune thrombocytopenia (ITP) is an autoimmune disease characterized by isolated thrombocytopenia (<100,000/ μ l). In patients newly diagnosed with ITP, treatment is initiated if thrombocyte count is <30,000/ μ l or if bleeding is present. Corticosteroids are the first treatment option. Second-line treatment is initiated in unresponsive patients and/or in the case of relapse ITP. Splenectomy, rituximab and thrombopoietin receptor agonists are currently make up the most effective second-line treatments. One of the causes of relapse after splenectomy in patients with ITP is the presence of an accessory spleen. Herein, we present a patient who relapsed 3 months after splenectomy and whose accessory spleen was detected 6 years post-splenectomy and at the third abdominal ultrasonography (USG) examination. We aimed to emphasize the importance of insisting on splenic investigation in patients with ITP who have relapsed post-splenectomy.

Keywords: Primary immune thrombocytopenia; Accessory spleen; Splenectomy

Introduction

The pathogenesis of (ITP) is related to a combination of increased platelet destruction and impaired platelet production caused principally by antiplatelet autoantibodies. ITP is a common acquired bleeding disorder. ITP is often a chronic disease in adults. The clinical manifestations of ITP are all mostly related to bleeding and/or thrombocytopenia; fatigue occurs in some patients. The goal of (ITP) therapy is to provide a safe platelet count to prevent clinically important bleeding, rather than to normalize the platelet count. For all patients with persistent ITP who have experienced clinically important bleeding despite first-line therapy with glucocorticoids, second-line therapy should be evaluated. Options for second line therapy include splenectomy, rituximab, and thrombopoietin receptor agonists (TPO-RAs). Splenectomy and rituximab are both associated with durable

remissions off treatment. Occasionally, an accessory spleen causes late recurrence of ITP following splenectomy.

Case Report

A 45-year-old female patient was evaluated in our outpatient clinic with a complaint of recurrent bruising on her legs. The patient's initial complete blood count revealed a hemoglobin count of 14.4 g/dL, a white blood cell count of $11.900 \times 10^9/\mu$ l and a platelet count of $5.000 \times 10^9/\mu$ l. Thrombocytopenia was confirmed by peripheral blood smear. Other causes of secondary thrombocytopenia were excluded and the patient was diagnosed with immune thrombocytopenia.

On physical examination, there were no significant findings except for petechial and ecchymosis on both lower extremities. The patient was prescribed 1 mg/kg prednisone and partial response to steroid treatment was obtained. The patient ultimately underwent a splenectomy because of the loss of partial response upon follow-up as she demonstrated irregular control thrombocyte measurements. Splenectomy was performed 15 months after the initial diagnosis and a partial response to splenectomy lasting about 3.5 months was observed. Thrombocytopenia repeated 3.5 months after splenectomy and prednisone and azathioprine were given for 9 months. The patient was then followed for six years without treatment.

However, thrombocytopenia repeated after 6 years. The patient was once again prescribed prednisone 1 mg/kg/day in addition to eltombopag 25 mg/day. Abdominal USG evaluations performed 6 months post-splenectomy and later 6 years post-splenectomy, did not report presence of an accessory spleen. The third and final abdominal USG of the patient with refractory thrombocytopenia revealed an accessory spleen measuring 1.5 cm. Computed tomography (CT) performed following the abdominal ultrasonography confirmed presence of an accessory spleen. In the case of the patient being presented, the accessory spleen detected in USG and CT was not observed in 3mCI Tc99m-sulfide colloid scintigraphy. A second splenectomy was planned for removal of the accessory spleen (Figure 1).

Discussion

The aim of treatment in patients with primary immune thrombocytopenia (ITP) is to obtain a safe platelet count to prevent clinically significant bleeding (major bleeding) rather than normalizing the platelet count [1,2]. In light of this information, treatment indications for newly diagnosed ITP patients include, (I) thrombocyte counts below 30,000/ μ l and (II) platelet counts above 30,000/ μ l in correlation with clinically significant bleeding.

Corticosteroids make-up the first-line treatment of patients newly diagnosed with ITP. Intravenous immunoglobulin and Anti-(Rh) D are other treatment options. In primary care, standard dose prednisone or methylprednisolone (1-2mg/kg/day), or high-dose dexamethasone (40 mg/day) is administered as corticosteroid therapy. 65-85% of newly diagnosed ITP patients respond to standard dose prednisone or methylprednisolone (3). Recently, studies comparing the efficacy of dexamethasone and prednisone treatments have been increasing. These studies, have reported that cases diagnosed with ITP respond earlier to dexamethasone treatment and that response rates are higher than those obtained using prednisone [3,4].

However, in a meta-analysis published in 2016, dexamethasone treatment has not been shown to be superior to prednisolone therapy in the long-term and in contrast to the early stages of treatment [5]. Most newly diagnosed ITP patients who respond to corticosteroid treatment have long-term relapse. In patients with ITP who have no response to relapse and/or relapse to first-line treatment, second-line treatment is initiated. Splenectomy, rituximab and thrombopoietin receptor agonists are the most important current second-line treatments.




Figure 1: Accessory spleen detected in ultrasonographic examinations.

Approximately 80% of ITP patients respond to splenectomy and in 60-65% of patients this response continues for many years [6,7]. On the other hand, nearly 15% of ITP patients that respond to splenectomy develop relapse after splenectomy [8]. As in the case of our patient, most of relapses develop shortly after splenectomy [8,9]. However, it is reported that relapse may occur up to 30 years post-splenectomy [10]. One of the major causes of relapse post-splenectomy is the presence of an accessory spleen. It is for this reason that evaluations (ultrasonography, computed tomography, etc.) to detect presence of an accessory are routinely performed in patients prior splenectomy. Nevertheless, despite preoperative investigations, routine examination may fail to detect an accessory spleen, or an accessory spleen may be overlooked during splenectomy.

In addition, a resting accessory spleen may hypertrophy post-splenectomy to compensate absence of primary splenic tissue. It has been hypothesized that, contamination of neighboring tissues with spleen cells during splenectomy may also cause the development of an accessory spleen [11]. Phom et al. reported that accessory spleen was detected in 14 (31%) of 45 ITP patients who experienced relapses post-splenectomy [12]. In another study, it is stated that the incidence of accessory spleen can be as high as 50% in cases of relapse after splenectomy [13]. ITP patients who develop relapse due to the presence of an accessory spleen respond to second splenectomy. Therefore, it is recommended that splenectomy be performed again in ITP patients with relapse due to accessory spleen.

Conclusion

Although the patient presented in this study experienced a relapse 3 months after splenectomy, it was only possible to detect accessory spleen after 6 years and at the third ultrasonography examination. We concluded that the most important reason for detecting accessory spleen in repeat ultrasonography examinations is associated with compensatory hypertrophy. In conclusion, in patients with ITP who develop relapse post-splenectomy, accessory spleen should be investigated and if the accessory spleen cannot be detected in initial examinations, it would be appropriate to continue the investigation of accessory spleen at close intervals and with persistency.

References

1. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, et al. (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. *Blood* 113: 2386-2393.
2. Ghanima W, Godeau B, Cines DB, Bussel JB (2012) How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. *Blood* 120: 960-969.
3. Cheng Y, Wong RSM, Soo YOY, Chui CH, Lau FY, et al. (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. *N Engl J Med* 349: 831-836.
4. Wei Y, Ji X, Wang Y, Wang J, Yang E, et al. (2016) High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. *Blood* 127: 296-302.
5. Mithoowani S, Gregory-Miller K, Goy J, Miller MC, Wang G, et al. (2016) High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. *Lancet Haematol* 3: e489-e496.
6. Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, et al. (2003) Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). *Am J Hematol* 72: 94-98.
7. Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, et al. (2005) Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. *Haematologica* 90: 72-77.
8. Woo JH, Park SH, Park YK, Choi CB, Choi YY, et al. (2004) Postsplenectomy recurrence of thrombocytopenia with an accessory spleen. *Korean J Intern Med* 19: 199-201.
9. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. *Blood* 97: 2549-2554.
10. Budzynski A, Bobrzyński A, Sacha T, Skotnicki A (2002) Laparoscopic removal of retroperitoneal accessory spleen in patient with relapsing idiopathic thrombocytopenic purpura 30 years after classical splenectomy. *Surg Endosc* 16: 1636.
11. Leo CA, Pravisani R, Bidinost S, Baccarani U, Bresadola V, et al. (2015) Postsplenectomy recurrence of idiopathic thrombocytopenic purpura: role of laparoscopic splenectomy in the treatment of accessory spleen. *G Chir* 36: 153-157.
12. Phom H, Kumar A, Tripathi M, Chandrashekar N; Choudhry VP, et al. (2004) Comparative evaluation of Tc-99m-heat-denatured RBC and Tc-99m-anti-D IgG opsonized RBC spleen planar and SPECT scintigraphy in the detection of accessory spleen in

postsplenectomy patients with chronic idiopathic thrombocytopenic purpura. *Clin Nucl Med* 29: 403-409.

13. Olsen WR, Beaudoin DE (1969) Increased incidence of accessory spleens in hematologic disease. *Arch Surg* 98: 762-763.